biOasis Technologies Inc. is an early stage biopharmaceutical company focused on research, development and commercialization of technologies and products intended for diagnosis and treatment of central nervous system (CNS) diseases and other disorders located within the brain. As of February 29, 2012, the Company was engaged in the development of a vector (Transcend) for the transport of therapeutic agents across the blood brain barrier (BBB), and the development of an in vitro diagnostic assay to assist physicians in diagnosis of Alzheimer�s disease (Cognitest). During the fiscal year ended February 29, 2012 (fiscal 2012), SISCAPA Assay Technologies, Inc., refined and streamlined the SISCAPA assay for p97. SISCAPA assays are being used as an analytical reference for the samples being evaluated in the Cognitest program.